top of page
Product/
Indication
2023
2024
2025
2026
2027
LXM.1
Epilepsy
LXM.4
Rheumatoid Arthiritis
LXM.5
Parkinson's Disease
LXM.6
Treatment of Renal Cell Carcinoma
LXM.9
Antidepressants
LXM.10
Thromboembolism
LXM.11
Thromboprophylaxis
LXM.12
Prostate Carcinoma
2028 +
LXM.2
Diabetes/ Metabolic Syndrome
Laxxon has both an external pipeline and an in-house Advanced Patented Generic pipeline.
All products created with our SPID®-Technology manufacturing approach are patent protected, whether engineered in-house or with an external partner.
![Laxxon - [screen printing (white)].png](https://static.wixstatic.com/media/7a2e6b_7f598b48393c4b0e830f42edb0fb615d~mv2.png/v1/fill/w_100,h_62,al_c,q_85,usm_0.66_1.00_0.01,blur_3,enc_auto/7a2e6b_7f598b48393c4b0e830f42edb0fb615d~mv2.png)
Product Pipeline
Laxxon has both an external pipeline and an in-house Advanced Patented Generic pipeline.
All products created with our SPID®-Technology manufacturing approach are patent protected, whether engineered in-house or with an external partner.
bottom of page